HLS Therapeutics Inc. has released its financial results for Q2 2025, reporting revenue of $14.2 million, a slight decrease from $14.5 million in the same period last year. The company's Adjusted EBITDA saw a significant increase to $5.2 million from $4.3 million, while cash from operations grew to $4.6 million from $2.5 million. Year-to-date revenue was $26.8 million, slightly down from $27 million, but Adjusted EBITDA increased to $9.0 million from $7 million, and cash from operations rose to $8.1 million from $3.3 million during the same period in 2024. Canadian product sales for Vascepa and Clozaril remained flat in Q2 2025 but were up 6% year-to-date. In the U.S., Clozaril sales increased by 1% in Q2 and 2% year-to-date. Royalty revenue declined significantly, down 65% in Q2 and 69% year-to-date, following the sale of the Xenpozyme royalty interest in Q2 2024. Operating expenses, excluding the cost of sales, decreased by 18% in Q2 and 19% year-to-date. The company also made principal repayments on its long-term debt totaling $8.5 million and expanded its cardiovascular portfolio by licensing Canadian rights to NEXLETOL and NEXLIZET from Esperion Therapeutics. Looking ahead, HLS Therapeutics expects Health Canada approval for NEXLETOL and NEXLIZET by year-end, with a launch planned for Q2 2026. The company anticipates these medicines will significantly enhance its cardiovascular business in Canada.